Skip to content
10-K

Annual Report

TONIX PHARMACEUTICALS HOLDING CORP. TNXP

0001999371-26-005730

← back to feed
Filed
Mar 12, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 11, 2026 13.41M sh
Shares Diluted FY 2025 · Dec 31, 2025 8.51M sh
Shares Diluted FY 2025 · Dec 31, 2024 736.34K sh
Stock Repurchased FY 2025 · Dec 31, 2025 $13.76M
Capex FY 2025 · Dec 31, 2025 $3.37M
Capex FY 2025 · Dec 31, 2024 $120K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$99.84M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$60.93M
Cash And Equivalents FY 2025 · Dec 31, 2025 $207.64M
Cash And Equivalents FY 2025 · Dec 31, 2024 $98.78M
Stockholders Equity FY 2025 · Dec 31, 2025 $245.15M
Stockholders Equity FY 2025 · Dec 31, 2024 $139.56M
Stockholders Equity FY 2025 · Dec 31, 2023 $105.53M
Current Liabilities FY 2025 · Dec 31, 2025 $30.84M
Current Liabilities FY 2025 · Dec 31, 2024 $18.31M
Total Liabilities FY 2025 · Dec 31, 2025 $32.02M
Total Liabilities FY 2025 · Dec 31, 2024 $23.33M
Current Assets FY 2025 · Dec 31, 2025 $228.88M
Current Assets FY 2025 · Dec 31, 2024 $119M
Total Assets FY 2025 · Dec 31, 2025 $277.17M
Total Assets FY 2025 · Dec 31, 2024 $162.89M
Eps Diluted FY 2025 · Dec 31, 2025 −$14.57
Eps Diluted FY 2025 · Dec 31, 2024 −$176.60
Eps Basic FY 2025 · Dec 31, 2025 −$14.57
Eps Basic FY 2025 · Dec 31, 2024 −$176.60
Sga Expense FY 2025 · Dec 31, 2025 $87.68M
Sga Expense FY 2025 · Dec 31, 2024 $40.1M
Rd Expense FY 2025 · Dec 31, 2025 $44.49M
Rd Expense FY 2025 · Dec 31, 2024 $39.97M
Net Income FY 2025 · Dec 31, 2025 −$124.02M
Net Income FY 2025 · Dec 31, 2024 −$130.04M
Operating Income FY 2025 · Dec 31, 2025 −$125.7M
Operating Income FY 2025 · Dec 31, 2024 −$136.7M
Cost Of Revenue FY 2025 · Dec 31, 2025 $6.64M
Cost Of Revenue FY 2025 · Dec 31, 2024 $7.77M
Revenue FY 2025 · Dec 31, 2025 $13.11M
Revenue FY 2025 · Dec 31, 2024 $10.09M
Long Term Debt FY 2025 · Dec 31, 2024 $4.67M
Short Term Debt FY 2025 · Dec 31, 2024 $2.82M